---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-132452"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:59:39.672137+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Terns reports positive Phase 1 CARDINAL data for TERN-701 in CML; MMR rate 50% at 3 months

## Summary
- 15 patients enrolled across 160mg, 320mg, 400mg QD; 14 of 15 remain on treatment as of Oct 28, 2024 cutoff.
- Cumulative MMR rate 50% (5/10) in non-T315i patients with ≥3 months treatment or MMR at baseline.
- No dose-limiting toxicities, AE-related discontinuations, dose reductions, or Grade 3+ treatment-related AEs.
- At 160mg and 320mg, free drug concentrations 4- and 8-fold above efficacious in vivo exposures.
- Dose expansion to start 1H25; longer-term MMR data expected in 4Q25.

## SEC filing metadata
- accession: 0000950170-24-132452
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017024132452/0000950170-24-132452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017024132452/tern-20241203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-132452
- JSON: https://secwatch.observer/filing/0000950170-24-132452.json
- Plain text: https://secwatch.observer/filing/0000950170-24-132452.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.